



**Xcess Biosciences Inc.**

7144 N Harlem Ave #169  
Chicago, IL 60631 USA

<http://www.xcessbio.com>


Toll free: 1-866-706-2330

Fax: 1-619- 810-0718

Email: [info@xcessbio.com](mailto:info@xcessbio.com)

## Wnt/ $\beta$ -catenin Inhibitor – KYA1797K

**Chemical Name:** potassium (Z)-3-(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoate



Molecular Weight:	442.50
Formula:	C <sub>17</sub> H <sub>11</sub> KN <sub>2</sub> O <sub>6</sub> S <sub>2</sub>
Purity:	≥98%
CAS#:	n/a
Solubility:	DMSO up to 100 mM
Storage	Powder: 4 °C 1 year DMSO: 4 °C 3 months -20 °C 1 year

### Biological Activity:

KYA1797K is a highly potent and selective Wnt/ $\beta$ -catenin inhibitor with IC<sub>50</sub>~0.75  $\mu$ M (TOPflash assay). It binds directly to the regulators of G-protein signaling domain of axin, initiating  $\beta$ -catenin and Ras degradation through enhancement of the  $\beta$ -catenin destruction complex activating GSK3 $\beta$ . KYA1797K can effectively suppress the growth of CRCs harboring APC and KRAS mutations, as shown by various in vitro studies and by in vivo studies using xenograft and transgenic mouse models of tumors induced by APC and KRAS mutations. Destabilization of both  $\beta$ -catenin and Ras via targeting axin is a potential therapeutic strategy for treatment of CRC and other type cancers activated Wnt/ $\beta$ -catenin and Ras pathways.

### How to Use:

**In vitro:** KYA1797K was suggested to be used at 25  $\mu$ M final concentration in vitro.

**In vivo:** KYA1797K was used to dose mice at 20-25 mg/kg by intraperitoneal injection in xenograft model of D-MT cell line that harbors both APC and KRAS mutations, or in Apc<sup>min/+</sup>/Kras<sup>G12D</sup> LA2 mouse model.

### Reference:

1. Cha PH, et al. Small-molecule binding of the axin RGS domain promotes  $\beta$ -catenin and Ras degradation. (2016) Nat Chem Biol. 12(8):593-600.

Products are for research use only. Not for human use.